In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

In Vino Veritas (IVV) Study: Randomized trial comparing long-term effects of red and white wines on markers of atherosclerosis and oxidative stress.

Session Novel insights into lifestyle and cardiovascular prevention

Speaker Milos Taborsky

Congress : ESC Congress 2014

  • Topic : preventive cardiology
  • Sub-topic : Lipids
  • Session type : Abstract Session
  • FP Number : 1027

Authors : M Taborsky (Olomouc,CZ), P Ostadal (Prague,CZ), T Adam (Olomouc,CZ), D Rihova (Prague,CZ)


M. Taborsky1 , P. Ostadal2 , T. Adam3 , D. Rihova2 , 1Palacky University, Faculty of Medicine and Dentistry, 1st Dept of Internal Medicine-Cardiology - Olomouc - Czech Republic , 2Na Homolce Hospital - Prague - Czech Republic , 3Palacky University, Faculty of Medicine and Dentistry, Clinical Biochemistry - Olomouc - Czech Republic ,

On behalf: Czech National Telemedicine Center

European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 181

Background: Since the early 90s, a growing body of evidence has indicated that the mild to moderate consumption of wine, has a protective effect against cardiovascular diseases.

Methods: The IVV study is a first long-term, prospective, multicenter, randomized trial comparing the effects of red (RW) and white wine (WW) on atherosclerosis markers. 146 healthy subjects at mild to moderate risk of atherosclerosis have been randomized to a regular consumption of red wine (Pinot Noir) or white wine (Chardonnay-Pinot) /1 producer, 1 terroir/ for one year (women 0,2 l, men 0,3 l, 5 times a week, logbook for wine and other alcoholic beverages consumption). The primary endpoint is the level of HDL-cholesterol at one year, secondary endpoints are the levels of other markers of atherosclerosis (LDL-cholesterol, C-reactive protein) and oxidative stress (Lp-PLA2, Copeptin).

Results: The level of HDL significantly decreased at 6 months in WW group in comparison with baseline value (Table 1). We did not detect any differences in the levels of ALT, GGT or bilirubin.

Conclusion: In this prospective randomized trial we did not find between long-term mild consumption of red or white wine any clinically relevant differences in the lipid profile, CRP, fasting blood glucose, other markers of atherosclerosis i.e. Lp-PLA2 or copeptin, and liver function tests. Moreover, we were unable to confirm the hypothesis coming mostly from the retrospective studies that wine drinking is associated with elevation of HDL.

The study is registred by ISRCTN under Ref. No. 54359610.

Table 1. Change in endpoints at 6 and 12 months from the enrollment according to wine
Mean (SD)TotalWhite wineRed winep
 At the enrollment1.66 (0.58)1.66 (0.66)1.65 (0.50)0.912
 At 6 months1.58 (0.48)1.54 (0.52)1.62 (0.43)0.317
 Difference 1−0.09 (0.34)−0.14 (0.41)−0.04 (0.26)0.074
 At 12 months1.62 (0.49)1.60 (0.53)1.64 (0.46)0.634
 Difference 2−0.04 (0.36)−0.07 (0.42)−0.01 (0.29)0.362

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are